Greater Noida, Apr 24 : Reinforcing its commitment to making advanced Cancer Care more accessible and patient-centric, ShardaCare-Healthcity, the largest super speciality hospital in Greater Noida, today announced a significant strengthening of its Oncology programme, establishing Greater Noida’s first complete Cancer Care Center, with the onboarding of four senior specialists across Surgical and Medical Oncology. The expansion includes the appointment of Dr. Malay Nandy as Senior Director & Head, Medical Oncology, Dr. Parveen Mendiratta as Director & Unit Head, Surgical Oncology, Dr. Sanjeev Kumar Tuli as Associate Director, Surgical Oncology, and Dr. Ruchir Tandon as Senior Consultant, Medical Oncology.
With these additions, the Oncology programme at ShardaCare-Healthcity now brings together a robust, multidisciplinary team, along with existing team members including Dr. Hemkant Verma, Senior Consultant & Unit Head - (Surgical Oncology), Dr. Anil Thakwani, Director & Head, Radiation Oncology, Dr. Anindya Mukherjee, Senior Consultant, Medical Oncology, and Dr. Swarnita Sahu, Associate Consultant in Radiation Oncology. The team is supported by a highly trained nursing and clinical support staff, collectively forming a comprehensive, patient-focused oncology unit equipped to manage a wide spectrum of cancer cases.
Cancer incidence is witnessing a steady rise in India, making it a major public health concern. According to GLOBOCAN 2022, the country reported over 1.46 million new cases, with a projected 12–15% increase by 2030. Cancer-related mortality remains high at over 850,000 deaths annually, largely due to late diagnosis, limited awareness, and restricted access to specialised care. Despite advancements, many patients continue to face fragmented treatment pathways and delayed interventions, thus impacting outcomes and survival rates.
In response to these challenges, ShardaCare-Healthcity’s strengthened Oncology programme bridges gaps between rising case volumes and access to coordinated, high-quality care by integrating medical, surgical, and radiation oncology within a single ecosystem. It delivers seamless, end-to-end cancer care - from diagnosis and treatment planning to advanced therapies and survivorship support, thus enhancing accessibility to specialised treatments and enabling the management of advanced and complex cancer cases. The programme offers chemotherapy, immunotherapy, targeted and endocrine therapy, personalised plans, daycare and regional chemotherapy; minimally invasive, robotic and laparoscopic surgeries, organ-specific resections, and reconstructive procedures; along with advanced radiotherapy including IMRT, IGRT, VMAT, stereotactic radiosurgery, brachytherapy, and precision image-guided treatments, enabling highly targeted and effective care under one roof.
Dr. Kousar Shah, Group CEO, ShardaCare-Healthcity, said,
“Cancer care in India is at a critical inflection point, where rising incidence is placing unprecedented pressure on healthcare systems. At ShardaCare-Healthcity, our focus is on building an integrated oncology ecosystem that not only delivers advanced treatment but also ensures continuity, accessibility, and patient-centric care. The expansion of our oncology team reflects our commitment to bridging existing gaps and enabling patients to access comprehensive, high-quality cancer care closer to home.”
The strengthening of ShardaCare-Healthcity’s Oncology programme marks a significant step in addressing India’s evolving cancer landscape. By combining clinical expertise, advanced technologies, and a multidisciplinary approach, the institution is enhancing treatment capabilities while shifting from fragmented care to a more coordinated, patient-centric model. Its efforts align with the urgent need to improve early access, enable precision-led treatment, and ensure comprehensive support across the patient journey.